Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Controlled, Double-Masked, Multi-Center, Comparative, In Parallel Groups (For 24 Weeks), To Compare The Efficacy And Safety of 0.3 mg Pegaptanib Sodium, With Sham Injections, and Open Study (for 30 Weeks) to Confirm the Safety of 0.3 mg Pegaptanib Sodium in Subjects With Diabetic Macular Edema (Dme).

Next Previous
Trial Profile

A Phase 3, Randomized, Controlled, Double-Masked, Multi-Center, Comparative, In Parallel Groups (For 24 Weeks), To Compare The Efficacy And Safety of 0.3 mg Pegaptanib Sodium, With Sham Injections, and Open Study (for 30 Weeks) to Confirm the Safety of 0.3 mg Pegaptanib Sodium in Subjects With Diabetic Macular Edema (Dme).

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 17 Jul 2013

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pegaptanib (Primary)
  • Indications Diabetic macular oedema
  • Focus Therapeutic Use

Most Recent Events

  • 01 Aug 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
  • 27 Jun 2012 Status changed from suspended to active, no longer recruiting as reported by ClinicalTrials.gov.
  • 25 May 2012 Status changed from active, no longer recruiting to suspended as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top